Skip to main content

Featured

5 Things to Know Today: CPI 3.1%, TSX Slides, China Tariff Cuts – Nov 17

  Tuesday, November 17, 2026 – Inflation held steady at 3.1%, the TSX slid to an 11-day low, the loonie dipped under 70 US cents and China agreed to cut tariffs on Canadian goods. Here are the five things to know today. Monday, Nov. 16 close Level / change Move S&P/TSX Composite 35,722.13 -383.77 (-1.06%) Dow Jones — -739.38 (-1.41%) S&P 500 — -145.08 (-1.92%) Nasdaq Composite — -626.52 (-2.50%) WTI crude (US$/bbl) 85.72 -3.21% USD/CAD (loonie ≈ 69.96¢ US) C$1.4293 Loonie softer Sources: Reuters, Xinhua, EconoTimes/FXStreet. Figures as of Monday’s close; loonie as quoted Tuesday morning. 1. Inflation held at 3.1% in October – and core measures cooled Statistics Canada said the Consumer Price Index rose 3.1% from a year earlier, matching September and a touch below the 3.2% economists expected. Prices rose 0.2% from the previous month. Gasoline was 30.9% higher than a year ago, but fell 2.5% from September, and CPI excluding energy eased to 2.0%. The Bank of Canada’s prefe...

article

Alzheimer’s vaccines get a boost from new drug approval

 

After decades of disappointment and controversy, the field of Alzheimer’s disease research has finally seen a breakthrough with the approval of the first drug that targets the underlying pathology of the condition. 

Aducanumab, a monoclonal antibody that clears amyloid plaques from the brain, was granted accelerated approval by the US Food and Drug Administration in June 2021, despite mixed results from clinical trials and objections from some experts. 

The drug’s approval has rekindled interest in other therapeutic approaches that aim to prevent or slow down the progression of Alzheimer’s, such as vaccines that stimulate the immune system to attack amyloid or tau, another protein that accumulates in the brains of people with the disease. 

Several vaccine candidates are currently in various stages of development and testing, and some researchers are optimistic that they could offer a more effective and convenient way to treat Alzheimer’s than infusions of antibodies.


Comments